The authors of “Targeted inactivation of β1 integrin induces β3 integrin switching, which drives breast cancer metastasis by TGF-β” (Mol. Biol. Cell [2013] 24, 3449–3459; originally published in MBoC In Press as 10.1091/mbc.E12-10-0776) wish to make a correction to the text of the article. In the original HTML and PDF versions, two numbers in column 1 of Table 1 are incorrect. The numbers are listed as 324.45 (±70.8) and 110.4 (±15.8)*, but should be 110.4 (±15.8)* and 324.45 (±70.8)*. The corrected Table appears below.
TABLE 1:
Functional disruption of β3 integrin inhibits primary tumor growth.
| Experimental condition | Final tumor volume (mm3) | Final tumor weight (mg) |
|---|---|---|
| Experiment 1 | ||
| Green fluorescent protein | 110.4 (±15.8)* | 187.4 (±23.2) |
| WT-β3 integrin | 324.45 (±70.8)* | 426.7 (±39.6)* |
| D119A-β3 integrin | 59.5 (±11.5)* | 148.5 (±29.1) |
| Experiment 2 | ||
| Scram | 1233.9 (±40.2) | 132.2 (±8.3) |
| Shβ3 integrin | 694.6 (±47.3)** | 71.0 (±7.3)*** |
Parental (GFP) or WT-β3 integrin– or D119A-β3 integrin–expressing 4T1 cells (12,000 cells/mouse; experiment 1) and parental (Scram) or β3 integrin-deficient 4T1 cells (10,000 cells/mouse; experiment 2) were engrafted into the fat pads of syngeneic BALB/c mice. Tumor development was monitored over a span of 4 wk. Data are mean (±SE; n = 5) final tumor volumes and weights (*p < 0.05; **p < 0.0005; ***p < 0.000005).
The HTML and PDF versions were corrected on January 20, 2014. These corrections may not appear on copies of the article that reside on other websites.